• Editorial: ECMO in the Cath Lab—Increasing Interventional Options for the ‘High Risk’ Patient

    In this issue, Brscic et al. report single-center extracorporeal membrane oxygenation (ECMO) use in 27 high-risk surgically ineligible patients requiring coronary and/or structural intervention [  ]. The mean age was 80, and the majority of patients had heart failure and were diabetics.

    Evidence for hemodynamic support in high-risk coronary interventions is well-recognized, with US Food and Drug Administration approval for the percutaneous microaxial catheter (Impella®, Abiomed, Danvers, MA, on March 23, 2015) but less so with ECMO [  ,  ]. ECMO use is even rarer with transcatheter aortic valve implantation (TAVI) [  ]. There are limited case reports for MitraClip® (Abbott Park, IL, USA) [  ,  ]. This paper addresses ECMO use with combined coronary and structural interventions.

    Author bio

    Cardiovascular Revascularization Medicine, 2021-11-01, Volume 32, Pages 68-68


    Read the full article on Science Direct: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S1553838921005479?returnurl=null&referrer=null

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details